PubMed Health⌕ Search

Biomedical subjects

M Steruská

Publications and source records attributed to M Steruská.

At least 19 recordsLinked to original sources
PubMed1993

Prognostic value of plasma-cell immunophenotype in patients with multiple myeloma.

A review is given of the prognostic significance of immunophenotyping of blood lymphoplasmocytic cells. From a group of 250 patients followed from 1981 through 1991 a subgroup of 70 patients (followed 1986 through 1991) were phenotyped at 6-month intervals by immunofluorescence tests with monoclonal antibodies for cytoplasmic immunoglobulin, kappa-lambda index, CD71, CD10, CD20, CD38, and HLA-DR receptors. In course of a longitudinal study it was found that prognostic significance for shortened survival can be derived from the presence of circulating CD10, CD71, and CD20 positive undifferentiated cells in peripheral blood. There was a correlation between increase of CALLA positive and CD71 positive cells. Further, an increase of undifferentiated clone occurred during transition of the disease to an aggressive phase. The median survival of the total group of 250 patients treated by the VMCP/MOCCA protocol, according to statistical analysis, was 90 months, the median survival of the aggressive stage with plasmoblastic and lymphoplasmocytic cell type, respectively, was only 12 months. The significance of phenotypization in the prognostic evaluation of variant heterogenous myeloma types is stressed.

Adult↗
PubMed1992

[Immunotyping of medullary and circulatory cells for prognostic evaluation of plasmacytoma].

The authors discuss the prognostic impact of immunophenotyping of circulating lymphoplasmatic cells in the peripheral blood stream in patients with generalized plasmocytoma. From a group of 250 patients followed up from 1981 to 1991 they selected a sub-group of 70 patients where they evaluated in 1986-1991 after six-month intervals the phenotype of medullary and circulating cells. They used the method of immunofluorescent detection of the presence of cytoplasmic Ig, the kappa-lambda index and phenotyping of antigens CD 9, CD 10, CD 20, CD 38, HLA-DR by monoclonal antibodies. In a longitudinal investigation of the survival period they revealed that the finding of circulating cells with signs of non-differentiation (presence of antigen CD 10 detected by antibody CALLA, presence of antigens B 1 (CD 20), CD 9 on circulating lymphocytes) has a prognostic meaning suggesting shorter survival. There was a direct correlation between the increase of CALLA positive cells and CD 9 positive cells. The authors found also that release of the clonus with signs of immaturity was present when the disease developed into the aggressive stage. While the group of 250 patients had according to statistical analyses, when treated according to protocol VMCP/MOCCA, a median survival of 90 months, the median survival of the aggressive stage (with the plasmoblast and lymphoplasmocytic type resp.) was only 12 months. The authors emphasize the prognostic importance of immunological typing of heterogeneous plasmocytoma populations.

Adult↗
PubMed1992

[Prognostication of chronic Ph+ myeloid leukemia using the PHCML.EXE computer program].

In 193 patients with Ph-positive chronic myeloid leukaemia (CML) Sokal's calculation formulae prognosticating initial risk status were applied, using the computer program PHCML. The aim of this study was to the prognostic reproducibility of these prognostic staging systems in our patient population. Our results confirm the previous conclusions that prognostic discrimination is possible at the time of diagnosis of CML but in our patients with poorer prognosis the stratification seems to be more accurate. No significant advantage was achieved when we prognosticated our patients younger than 46 years using the formula recommended by Sokal et al. specifically for younger patients. We analyzed different criteria when segregating patients in groups with better or poorer prognosis. We found that the coefficient of the patient's relative risk as the boundary, was 1.9 our patient's group contrary to 1.2 in Sokal's studies.

Adolescent↗
PubMed1990

[Monocytosis and myelomonocytic dysplasia in myelodysplastic syndrome].

Myelodysplastic syndrome (MDS) is frequently associated with monocytosis in the blood and myelomonocytic dysplasia in the bone marrow. In two groups of patients with MDS, all subtypes excluding CMML, the authors demonstrated that monocytosis was present in 15% of the patients in group I according to the haemogram at the time when the diagnosis was established and in 19% in group II where it was required that at least in half the haemograms throughout the course of the disease there were more than 10% monocytes. No difference was found in the prognosis of patients with monocytosis, as compared with patients with monocytopenia as regards the life span and frequency of transformation into AL. The cytogenetic and cultivation findings did not differ either. In some instances, in particular in patients with RA and RAS significant monocytosis was not associated with the expected proliferation of monocytoid cells in bone marrow. The authors assume that proliferation and differentiation of germ cells in the monocytic series is easier than in the granulocytic series and that monocytosis can be considered a manifestation of substituted neutropenia. The work indicates the difficulties associated with the differential diagnosis of RA, RAS and RAEB with monocytosis, MDS with a dominating change of the type of myelomonocytic dysplasia and CMML proper.

Anemia, Refractory↗
PubMed1990

[Possibilities of finding identical HLA donor-recipient pairs for bone marrow transplantation].

With the aim to detect genotypically identical donors for patients suffering from some type of leukemia or aplastic anemia, HLA antigens and MLC reactivity were determined in 72 families, having together 209 children. HLA identical, MLC negative sibling donors were found for 31 patients, i.e. 43%. Compared to the healthy population, no significant differences were found in the frequency of HLA antigens and haplotypes in 58 leukemic patients. Two recombinations were recorded, one between the loci HLA-A and HLA-B, and the other one between HLA-B and HLA-D/DR. Only 9 persons (2.5%) homozygous for HLA-D antigens were found in the whole series of 353 subjects investigated.

Bone Marrow Transplantation↗
PubMed1989

[Interferon alpha in the treatment of malignant hematologic diseases].

The majority of malignant haematological diseases is incurable by contemporary procedures and therefore new approaches are sought, based on recent findings on haematopoiesis and its regulation. One of the new approaches is the use of so-called biological response modifiers between the later interferons. Recently relatively abundant experience was assembled with therapy using alpha interferon. The author presents an account of hitherto achieved therapeutic results obtained with alpha interferon in neoplasias of myelopoiesis and lymphopoiesis.

Humans↗
PubMed1989

[Diabetes insipidus as the first cause of myelodysplastic syndrome].

The concurrent occurrence of myelodysplastic syndrome and diabetes insipidus is very rare. In the available literature so far only three cases were described. In acute leukaemia the concurrence of the two diseases is rare. The authors describe two cases of concurrent diabetes insipidus and myelodysplastic syndrome with typical clinical and laboratory symptoms. A 27-year-old man with refractory anaemia (according to the FAB classification of myelodysplastic syndrome) died after 10 months from complications of acute leukaemia. In a 58-year-old female patients with refractory anaemia after two years remission the condition deteriorated and developed into RASEB (refractory anaemia with excess of blast cells) according to the FAB classification with partial remission of the disease after cytostatic treatment. During permanent substitution treatment (Adiuretin Spofa) diabetes insipidus was compensated in both diseases.

Adult↗
PubMed1986

Results and further perspectives of plasmocytoma chemotherapy.

Polychemotherapy has improved prognostic parameters of survival in patients with plasmocytoma. The mean survival in patients given long-time prednisone and melphalan treatment is 20 months, in those given polychemotherapy over 30 months. In patients with a slow disease progression the combinations COPP and VMCP give satisfactory results in about 40%, but in a majority of patients more effective treatment is necessary. The authors compare the 5-year survival of two polychemotherapy groups with the prednisone and melphalan group. The mean survival after prednisone and melphalan was 33 months, after polychemotherapy (groups COPP, VMCP) 46 months and 57 months (VMCP + M2), respectively. Survival time was influenced by the clinical stage.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1984

Prognostic factors in chronic lymphocytic leukemia.

In respect to literary data, we tried to evaluate some qualitative and quantitative indices for prognosis of chronic lymphocytic leukemia (CLL). In the group of 117 patients we evaluated prognostic parameter proposed by Jaksic and Vitale, which takes into consideration so-called total tumour mass (TTM). In the group of patients investigated we did not succeed in confirmation of prognostic value of TTM scoring as determined at the time of CLL diagnosis. However, investigation of doubling time of total tumour mass (DT TTM) appeared to be more important. To determine reliable prognostic criteria for CLL, however, complex cooperative study on the greater group of patients is necessary.

Aged↗